Skip to content
CA.gov logo in white
  • Grants Management System
  • CIRM Hub Portal
  • Contact
  • About
    • Our Mission
    • Our Impact
    • Our Governing Board
    • Strategic Goals
    • Our Team
    • Annual Reports
  • For Researchers
    • Funding Opportunities
    • Information for Applicants
    • Researcher Resources
    • Our Review Process
  • Our Programs
    • Grants Dashboard
    • Research and Development
    • Education and Training
    • Patient Access
  • Patient Resources
    • Stem Cell and Genetic Research
    • From Bench to Bedside
    • Community Outreach
    • Clinical Trials
    • Community Stories
  • News and Events
    • Press Releases
    • Public Meetings
    • Blog
    • Webinars and Workshops
  • About
    • Our Mission
    • Our Impact
    • Our Governing Board
    • Strategic Goals
    • Our Team
    • Annual Reports
  • For Researchers
    • Funding Opportunities
    • Information for Applicants
    • Researcher Resources
    • Our Review Process
  • Our Programs
    • Grants Dashboard
    • Research and Development
    • Education and Training
    • Patient Access
  • Patient Resources
    • Stem Cell and Genetic Research
    • From Bench to Bedside
    • Community Outreach
    • Clinical Trials
    • Community Stories
  • News and Events
    • Press Releases
    • Public Meetings
    • Blog
    • Webinars and Workshops

BCMA/CS1 Bispecific CAR-T Cell Therapy to Prevent Antigen Escape in Multiple Myeloma

  • Post author:
  • Post published:August 27, 2026
  • Post category:

Translational Candidate A single-chain bispecific chimeric antigen receptor (CAR) targeting BCMA and CS1 will be used to in autologous T-cell therapy for multiple myeloma. Area of Impact Translational candidate will…

Continue ReadingBCMA/CS1 Bispecific CAR-T Cell Therapy to Prevent Antigen Escape in Multiple Myeloma

Neural Stem cell-mediated oncolytic immunotherapy for ovarian cancer

  • Post author:
  • Post published:August 27, 2026
  • Post category:

Translational Candidate A clinically tested tumor-tropic neural stem cell (NSC) platform for effective distribution of oncolytic virotherapy to ovarian cancer metastases Area of Impact This NSC-delivered virotherapy approach will lead…

Continue ReadingNeural Stem cell-mediated oncolytic immunotherapy for ovarian cancer

Developing engineered autologous leukemia vaccines to target residual leukemic stem cells

  • Post author:
  • Post published:August 27, 2026
  • Post category:

Translational Candidate A universally applicable, patient-specific leukemia vaccine engineered to express a novel immune stimulatory combination for post-remission therapy Area of Impact There is a critical and unmet need for…

Continue ReadingDeveloping engineered autologous leukemia vaccines to target residual leukemic stem cells

Human Embryonic Stem Cell-Derived Natural Killer Cells for Cancer Treatment

  • Post author:
  • Post published:August 27, 2026
  • Post category:

Translational Candidate Human embryonic stem cell (hESC)-derived natural killer (NK) cells to target relapsed/refractory Acute Myelogenous Leukemia (AML) Area of Impact hESC-derived NK cells provide a novel and potent approach…

Continue ReadingHuman Embryonic Stem Cell-Derived Natural Killer Cells for Cancer Treatment

A Splicing Modulator Targeting Cancer Stem Cells in Acute Myeloid Leukemia

  • Post author:
  • Post published:August 27, 2026
  • Post category:

Translational Candidate 17S-FD-895 is a potent small molecule splicing modulator that inhibits aberrant splicing in CSCs that have deregulated SF3B1 expression. Area of Impact Development of 17S-FD-895 could address a…

Continue ReadingA Splicing Modulator Targeting Cancer Stem Cells in Acute Myeloid Leukemia

Development of ROR1 CAR-T cells to target cancer stem cells in advanced malignancies

  • Post author:
  • Post published:August 27, 2026
  • Post category:

Translational Candidate Autologous ROR1 CAR-T cell transduced with a lentiviral vector containing scFv (cirmtuzumab) with CD28, CD137, CD3zeta signaling domains Area of Impact ROR1 expressing cancer stem cells in solid…

Continue ReadingDevelopment of ROR1 CAR-T cells to target cancer stem cells in advanced malignancies

Placental Derived Natural Killer Cells to Target Solid Tumor Cancer Stem Cells (CSC)

  • Post author:
  • Post published:August 27, 2026
  • Post category:

Translational Candidate Placental-derived stem cells becoming a unique NK-like cell Area of Impact solid tissue cancers Mechanism of Action These expanded cells share many characteristics as NK cells but appear…

Continue ReadingPlacental Derived Natural Killer Cells to Target Solid Tumor Cancer Stem Cells (CSC)

Stem Cell-Based iNKT Cell Therapy for Cancer

  • Post author:
  • Post published:August 27, 2026
  • Post category:

Translational Candidate Lenti/iNKT-sr39TK Modified Autologous Human CD34+ Hematopoietic Stem Cells (HSCs) Area of Impact The targeted area of impact for the candidate is cancer therapy, in particular cancers that are…

Continue ReadingStem Cell-Based iNKT Cell Therapy for Cancer

2nd Generation Vaccine for the Treatment of Glioblastoma

  • Post author:
  • Post published:August 27, 2026
  • Post category:

Translational Candidate It is the peptide LEEKKYNYVVVTDHC conjugated to KLH and used as an anti-cancer vaccine. Area of Impact This is a better optimized, more robust vaccine that aspires to…

Continue Reading2nd Generation Vaccine for the Treatment of Glioblastoma

62nd Midwinter Conference of Immunologists

  • Post author:
  • Post published:August 27, 2026
  • Post category:

Continue Reading62nd Midwinter Conference of Immunologists
  • Go to the previous page
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • …
  • 18
  • Go to the next page
  • Careers
  • Administrative & Financials
  • Accessibility

Subscribe to Receive CIRM News

Get the latest CIRM news, information on upcoming meetings, and funding opportunities delivered to your inbox. 

Sign Up
Facebook-f X-twitter Instagram Linkedin Youtube
  • Privacy Policy
  • ©2025 California Institute for Regenerative Medicine
  • Media Guidelines
  • Contact Us